Cogent Biosciences Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

Cogent Biosciences, Inc. (Nasdaq: COGT) announced upcoming participation in two major investor conferences. The first is the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 a.m. GMT (6:30 a.m. ET). The second is the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 11:00 a.m. ET. Live webcasts of these events will be available on Cogent's website, with replays archived for 30 days. Cogent focuses on precision therapies for genetically defined diseases, with its leading program targeting the KIT D816V mutation.

WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in the following upcoming investor conferences:

• Jefferies London Healthcare Conference - Wednesday, November 16, 2022 at 11:30 a.m. GMT (6:30 a.m. ET)
  

• Piper Sandler 34th Annual Healthcare Conference - Wednesday, November 30, 2022 at 11:00 a.m. ET

A live webcast of each event can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 30 days following each presentation.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO.

Contact:

Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

What are the dates and times for Cogent Biosciences' upcoming investor conferences?

Cogent Biosciences will participate in the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 a.m. GMT (6:30 a.m. ET) and the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 11:00 a.m. ET.

Where can I watch the Cogent Biosciences conference webcasts?

The live webcasts of Cogent Biosciences' conference presentations can be accessed on the Investors & Media page of their website.

What is the key focus of Cogent Biosciences?

Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, particularly targeting the KIT D816V mutation.

What is bezuclastinib, and what condition does it target?

Bezuclastinib is a selective tyrosine kinase inhibitor developed by Cogent Biosciences, targeting the KIT D816V mutation responsible for systemic mastocytosis and certain gastrointestinal stromal tumors.

How long will the webcasts of the Cogent conferences be available for replay?

Replays of the webcasts will be available approximately two hours after each event and archived for up to 30 days.